Carcinogenesis Advance Access published online on January 18, 2007
Carcinogenesis, doi:10.1093/carcin/bgm004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Soy Phytochemicals Synergistically Enhance the Preventive Effect of Tamoxifen on the Growth of Estrogen-Dependent Human Breast Carcinoma in Mice
Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
1 To whom correspondence should be sent: Jin-Rong Zhou, Ph.D., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Burlington-5, 330 Brookline Avenue, Boston, MA 02215. Telephone: (617) 632-9222. Fax: (617) 632-0275. E-mail: jrzhou{at}bidmc.harvard.edu
The objective of this work was to determine the interactive effects between soy bioactive components and tamoxifen (TAM) on prevention of estrogen-dependent breast cancer. We initially investigated the effects of soy isoflavone genistein and TAM on the growth and cell cycle progression of estrogen-dependent MCF-7 human breast cancer cells, and on the expression of ER
, pS2, and EGFR genes in vitro. Genistein or TAM alone inhibited the growth of MCF-7 cells in part via G1 phase arrest, but their combinations showed suggestive antagonistic effects. We further evaluated the effects of bioactive soy components and TAM on the growth inhibition of MCF-7 tumors in a clinically relevant breast tumor model. TAM and bioactive soy components, genistein and soy phytochemical concentrate (SPC), delayed the growth of MCF-7 tumors. The combination of TAM with genistein or SPC, especially at the lower dose of TAM, had synergistic effects on delaying the growth of MCF-7 tumors. Biomarker determination suggests that the combination of TAM and soy components may synergistically delay the growth of MCF-7 tumors via their combined effects on induction of tumor cell apoptosis and inhibition of tumor cell proliferation. In addition, genistein and TAM combination synergistically delayed the growth of breast tumor via decreased estrogen level and activity, and down-regulation of EGFR expression. The results from our studies suggest that further investigations may be warranted to determine if the combination of TAM and bioactive soy components may be used for prevention and/or treatment of estrogen-dependent breast cancer.
Key Words: soy phytochemicals • genistein • tamoxifen • breast cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. C. Olson, J. S. Link, J. R. Waisman, and T. C. Kupiec Breast Cancer Patients Unknowingly Dosing Themselves With Estrogen by Using Topical Moisturizers J. Clin. Oncol., September 10, 2009; 27(26): e103 - e104. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Davis, J. Mao, B. Naz, J. A Kohl, and C. S Rosenfeld Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus J. Mol. Endocrinol., October 1, 2008; 41(4): 205 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gallo, G. F. Zannoni, I. De Stefano, M. Mosca, C. Ferlini, E. Mantuano, and G. Scambia Soy Phytochemicals Decrease Nonsmall Cell Lung Cancer Growth In Female Athymic Mice J. Nutr., July 1, 2008; 138(7): 1360 - 1364. [Abstract] [Full Text] [PDF]
|
|